Greetings, and welcome to the Oncocyte Corporation first quarter of 2022 earnings conference call. At this time, all participants are in listen-only mode. A brief question- and- answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press Star then zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to turn the conference over to Mr. Tej Singh of Investor Relations. Thank you, operator, and thank you everyone for joining us for today's conference call to discuss Oncocyte's first-quarter 2022 financial results and recent operating highlights. If you have not seen today's financial results press releases, please visit the company's website on the Investors page. Before turning the call over to Ronnie Andrews, Oncocyte's President and Chief Executive Officer, I would like to remind you that during this conference call, the company will make projections and forward-looking statements regarding future events. Any statements that are not historical facts are forward-looking statements. We encourage you to review the company's SEC filings, including, without limitation, the company's Forms 10-K and 10-Qs, which identifies the risks, the specific risk factors that may cause actual results or events to differ materially from those described in the forward-looking statements. These factors may include, without limitation, risks inherent in the development and/or the commercialization of potential diagnostic tests, uncertainty in the results of clinical trials or regulatory approvals, the capacity of OncoCyte's third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, the need to obtain third-party reimbursement for patients' use of any diagnostic test the company commercializes, our need and ability to obtain future capital and maintenance of IP rights, risks inherent in strategic transactions such as failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, greater than estimated allocations of resources to develop and commercialize technologies, or failure to maintain any laboratory accreditation or certification, and uncertainties associated with the COVID-19 pandemic and its possible effects on our operations. Therefore, actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements. OncoCyte expressly disclaims any intent or obligation to update these forward-looking statements except as otherwise may be required under applicable law. With that, I'll turn the call over to Ronnie. Hey, thanks, Tej. Welcome everyone to our conference call to discuss first quarter 2022 financial results and operating highlights. On today's call, I'll review the significant progress we've made and continue to make across all of our major products as we move toward reimbursement submissions for our oncology menu and update you on our exciting opportunity in transplant. First, I think it's important to address the market headwinds and some important decisions we've made to better position Oncocyte to weather the current external environment. When I stepped into the CEO role in July of 2019, we introduced and adopted an ambitious vision to acquire companies that own technologies that could accelerate our path to deliver a complete menu of precision treatment decision and therapy monitoring tests to assist oncologists and pathologists in making more timely, informed decisions for their patients. Despite the challenging external market environment, I'm very proud to say we enter 2022 with every product on schedule and poised for submission for reimbursement over the next 12 months. Notwithstanding these favorable developments, we recognize the need to be fiscally prudent and strong stewards of capital. In connection with these objectives, the company, led by our board, determined to take actions to strengthen our balance sheet so as to ensure we have a solid path through 2023 and into 2024. In April, we successfully consummated an underwritten public offering of common stock and warrants with net proceeds of approximately $32.8 million. This financing round was accomplished with the strong support of several current investors as well as some new institutions. We very much appreciate the continued commitment to the company and to our vision. We believe this recent funding, combined with our current balance sheet, expected revenue ramp, as well as licensing and platform partnerships, will provide us sufficient capital into 2024. However, in order to do this, we've had to make some important prioritization decisions that I want to share with everyone today. First, we expect to shift from our current parallel path product development and launch processes and begin to focus on two main product priorities. For the foreseeable future, we intend to focus our organizational energies on, one, launching our recently CLIA-validated transplant monitoring test for liver transplant patients, as well as completing the platform partnership and initiating the clinical trials for an IVD kit submission in transplant. Two, completing the DetermaIO early adopter program and publishing supporting papers to drive future adoption, as well as submitting for CMS reimbursement in the second half of 2022. In Q1, we completed the investment required to build out our Irvine lab to accommodate the upcoming IVD development in both transplant and in oncology. Our exciting relationship with Thermo Fisher to build regulated content on their next-generation sequencing system, Genexus, required preparations and capital investments. Here in Q2, with the infrastructure investments now behind us, we have the facilities, the instruments, and the expert team in place to begin this important work, allowing us to start the regulatory process to position our oncology tests to launch ex-US through Thermo’s global channels. Before I dive into the product line progress we made in Q1, I'd like to address some organizational changes that I believe will assist us in our efforts. As of June 1st, Mitch Levine will move over to become Corporate Development Officer, where he will oversee the multiple initiatives underway for bringing in non-dilutive cash via licensing and partnership negotiations. We're grateful to Mitch for all his work as our CFO, and believe this move allows us even better leverage of Mitch's extensive capital markets experience and negotiation skills as we seek new sources of revenue. Also on June 1st, Anish John will be promoted to the role of Senior Vice President of Finance and Interim CFO. We originally recruited Anish to run our transplant business as Head of Operations and Finance, and he's done an exceptional job as evidenced by our completion of the LDT validation and the LCD submission for liver two months ahead of schedule. Anish has over 30 years of finance and operational experience within the diagnostics, life sciences, and high technology industry sectors, including molecular diagnostics companies like Foundation Medicine and PerkinElmer. Anish brings incredibly broad experience to the role, and he understands the challenge ahead and is uniquely qualified to help us deliver on our financial and cash management goals. In addition, while it saddens me personally, Cavan Redmond, our Chairman of the Board, has decided not to stand for re-election to the Board of Directors at our annual shareholder meeting this summer. Cavan has served shareholders extremely well for the past 6 years. However, in light of some very personal reasons, Cavan has determined that more time with family is needed and other life interests. We're extremely appreciative of the investment and time and experience he's made to OncoCyte over the years, and I'm grateful for his willingness to remain accessible as a trusted advisor to me and other members of management to ensure a seamless transition. In connection with Cavan's decision to not run for re-election, I'm pleased to announce that Andy Arno, our current Audit Chair, has been unanimously elected by our board to succeed Cavan. Andy brings a long history of financial acumen to the role, which we believe will ensure solid continuity as we navigate the current market environment and move OncoCyte forward. With that, let me now provide updates on our solid progress across our portfolio. First, I want to discuss our anticipated rapidly emerging revenue opportunity in transplant rejection monitoring. Last fall, we set out an ambitious plan to finalize our lab developed test for liver patients by the end of first half of 2022. As announced last week, thanks to the incredible effort by our teams in Germany and Nashville, we now have a fully CLIA-validated lab test for liver transplant monitoring poised for launch. The team was also able to complete the liver clinical validation for CMS submission two months ahead of plan, positioning us for a full market launch in the fall of this year. Building on our patents and numerous papers published based on our digital PCR methods, our two teams have streamlined the workflow, delivering an incredibly efficient digital PCR process that allows us to consistently, with solid assay reproducibility, complete the test process and report results within a single shift once our lab receives the patient's blood sample. We believe this will be the fastest turnaround time available in the industry today, and we're enthusiastic about the opportunity to provide this important test for liver patients, where today there is no current molecular monitoring test on the market. I look forward to updating you on our commercial plans on future calls. Now let's turn to our oncology portfolio. In the first quarter, DetermaRx grew 66% versus Q1 of 2021, and sample volumes were 73% above the prior year, reflecting continued momentum towards our stated goal of doubling 2021 volumes and revenues. In the first quarter, we continued to expand our pool of onboarded physicians, which is now up to 472. This is an increase of 10% year-over-year, and similarly, onboarded accounts also increased 10% to a total of 278 as of the end of first quarter. Let's turn next to DetermaIO. It's clear from our early adopter program that there's a tremendous need for a better solution to immunotherapy response prediction than the two prognostic tests that are currently available today. Over the course of first quarter, we've gained valuable insights as to the use cases for DetermaIO and have a clear understanding of its importance in early-stage triple-negative breast cancer and late-stage non-small cell lung cancer. We continue to build the foundation of supportive papers, expanding the clinical utility of the test and supporting the unique claim of DetermaIO's utility across multiple tumor types. Recently, at AACR, we presented data supporting its use in metastatic bladder cancer, our second major data set in this cancer type, which we believe is now statistically powered to allow us to expand into bladder cancer as our third tumor type. This June, at the American Society of Clinical Oncology or ASCO meeting, our collaborator will be releasing the results of the previously announced collaboration with the GONO Clinical Trials Group, where DetermaIO was tested as a biomarker on the AtezoTRIBE study. AtezoTRIBE is a randomized clinical trial in metastatic colorectal cancer where patients receive placebo or the standard of care plus the Roche drug Atezo. Last September, Dr. Cremolini, Dr. Chiara Cremolini of the GONO Clinical Trials Group reported the results of the trial where the trial was considered a success, but only for a very small population of patients. As has been previously seen in numerous studies, most of the benefit was seen in a subgroup of 5% of metastatic colorectal cancer patients that had a rare genetic mutation. It is now universally accepted that the remaining 95% of patients need a biomarker. In fact, without a predictive test, this very large patient population will continue to lack access to immune checkpoint inhibitors as a treatment option. Dr. Chiara Cremolini mentioned that her team's future work will be looking at biomarkers for these low responding patients, and DetermaIO is mentioned by name as a candidate. These important data will be released at ASCO. While today we cannot comment on the results, given it's a blinded study, we encourage you to stay tuned. I cannot overstate the importance of such a potential new indication for immune checkpoint inhibitors and for our DetermaIO program. Additionally, at ASCO, we're releasing data on DetermaIO and metastatic triple-negative breast cancer using the drug Keytruda. While we have previous data in TNBC, those studies were with different immune checkpoint inhibitors and in earlier stage tumors rather than metastatic disease. This could expand our applicable TNBC patient population for one of the leading immune checkpoint inhibitors, Keytruda. Finally, we'll be releasing new data in gastric cancer. While gastric cancer is not a common cancer in this country, it is the third leading cause of cancer-related deaths worldwide. We feel that this indication is important now that we solidified our platform and channel partnership with Thermo Fisher for rest of world markets and are already working on the kit version of DetermaIO. Needless to say, ASCO is an important meeting for DetermaIO, and we look forward to speaking with you further once the data is all public. Let me close by summarizing. Despite the external environment, I continue to be extremely enthusiastic about the progress we've made today. Looking ahead, we'll be taking steps to focus our investments on how we stage our product development and launches and have many exciting growth drivers for you to watch over the next six to eight quarters. We'll continue to drive sample volume growth and revenue increases for DetermaRx. Beginning in the second half of this year, we plan to start the sequencing of our four major product launches with our transplant monitoring offering in liver, followed by full market launch of DetermaIO, DetermaTx for the U.S. clinical oncology market. Finally, we expect to launch DetermaCNI in the U.S. for pharma clinical trial markets. Gaining reimbursement for our portfolio and bringing our test to market and generate revenue growth is essential. We believe that we've optimized the organization to drive external partnerships and licensing to generate additional revenue streams, and we've taken steps to reduce our burn to ensure our current resources carry us into 2024. We built a world-class organization that I'm very proud of, and I'm grateful for your support as we advance our platform to deliver life-changing tests to the patients, physicians we serve each day. At this point, I'd like to turn the call over to Mitch Levine to review our financials. Mitch? Hey, thanks, Ronnie. Hi, everyone. Our consolidated revenues for the first quarter of 2022 were approximately $1.4 million, up from $0.3 million from the same quarter a year ago. First quarter revenues associated with DetermaRx were $1.0 million, up from $0.2 million sequentially, and up $0.4 million year-over-year. We received $40,000 in licensing-related revenues in the first quarter from licensing our proprietary molecular test to China. After the close of the first quarter, we received the final Burning Rock milestone payment of $1 million according to our November 2021 amendment and will account for it as licensing revenue in the second quarter of 2022. Our pharma services business generated $0.4 million in the first quarter, a decrease of $0.1 million quarter-over-quarter, and a decrease of $0.1 million year-over-year. As we have discussed previously, revenues in pharma services will likely fluctuate as we receive samples from biopharma clinical trials. Cost of revenues for the first quarter was approximately $2.0 million, including $1.0 million from the cost of diagnostic tests and testing services we perform for our pharma customers and $0.9 million in non-cash amortization expenses of DetermaRx and pharma services-related intangibles. Cost of revenues also include testing services we perform for our pharma customers. Research and development expense for the first quarter of 2022 was $5.1 million, an increase of $1.8 million from the same period a year ago. The increase in R&D expense was related to increased headcount as we prepare to begin the clinical trials to build IVD kits for our platform partnerships, as well as increased R&D activity as we continue to support clinical trials to gain statistical power to our current Determa IO datasets to ensure success as we submit to CMS for reimbursement, as well as build our clinical efforts for our new transplant business. General and administrative expense for the first quarter of 2022 was $5.7 million, an increase of $900,000 for the same period in 2021, due primarily to an increase in personnel and related expenses. We saw increases in stock-based and cash compensation for our new hires and a standard cost of living increase for many employees. We also incurred professional legal fees as well as other acquisition and business development related costs, which we expect will be non-recurring. Sales and marketing expense for the first quarter of 2022 was $3.2 million, an increase of $1 million year-over-year, primarily attributable to an increase in headcount and continued ramp in sales and marketing activities to prepare for commercialization of our transplant business, as well as support the commercialization efforts of DetermaIO and DetermaRx. Non-GAAP operating loss, as adjusted for the first quarter of 2022, was $11.3 million, an increase of $3.9 million sequentially, and an increase of $2.7 million as compared to the same period a year ago. This increase is primarily attributable to an increase in headcount in several critical areas of the company. GAAP operating loss as reported for the first quarter of 2022 was $9.9 million, a decrease of $25.8 million quarter-over-quarter, mainly due to the $25 million change in contingent consideration recognized in Q4 2021, and a decrease of $1.5 million as compared to the same period a year ago. We have provided a reconciliation between these GAAP and non-GAAP operating losses in the financial tables, including with our earnings release. For the first quarter of 2022, we reported a GAAP net loss of $10.3 million or $0.11 per share as compared to $35.9 million or $0.39 per share, a decrease of $25.6 million quarter-over-quarter. Again, mainly due to the $25 million change in contingent consideration recognized in Q4 2021. $3.9 million An increase of $6.4 million as compared to the same period a year ago. Turning now to the balance sheet. As of March 31, 2022, we had cash equivalents, restricted cash and marketable securities of $22.7 million. Following the end of the first quarter, we raised $32.8 million in net proceeds from an underwritten offering of common stock priced at market. We anticipate receiving two tranches of $5 million preferred stock offerings in the second and fourth quarters of this year. The preferred is priced at a 20% premium to market. Additionally, we are currently reviewing several options for non-dilutive forms of capital, including capital lease lines, platform partnerships for transplant, licensing tests in the U.S. markets as well as commercial partnerships. We feel confident that our current balance sheet, combined with these non-dilutive opportunities, provide us with sufficient cash to take the company into 2024. As Ronnie mentioned, we are proactively preparing for continued market headwinds by reprioritizing on a more sequential approach to product development and test launches. Specifically, we plan to reduce the number of clinical studies we invest in over the next 18-24 months and rely on the data collected to date to support the submission for reimbursement and the subsequent product launches. We also plan to reevaluate timing of several capital intensive investments, including planned sales force expansion to launch DetermaTx and DetermaIO. These expense reductions, combined with the anticipated revenue growth once our tests receive reimbursement, is expected to have an immediate impact on reducing our cash burn. Net cash used in operations for the quarter was $13.3 million. Net cash used in operations increased sequentially due to timing of invoices that were paid in the first quarter rather than the fourth, as well as personnel, R&D and sales and marketing expenses. Note that net cash used in Q4 reflected a $2 million milestone payment from the Burning Rock licensing agreement. Looking ahead, we expect our Q1 cash usage for facilities build out and instrument purchases to be a one-time expense, and thus our operating cash usage will begin to decline over the future periods. We are committed to solid stewardship of the current cash on hand following our recent funding. As I transition into my new role as Head of Corporate Development, I want to take a moment to express my gratitude for the privilege of serving as your CFO the last five years. I look forward to working closely with Ronnie Andrews as we enter the next phase of our strategic initiatives and seek new global partnerships and licensing opportunities to bring increased capital and revenue to Insight Molecular Diagnostics. That concludes my remarks concerning our financial highlights. Operator, please open the call for questions. Thank you very much, sir. Ladies and gentlemen, we will now be conducting a question- and- answer session. If you would like to ask a question, please press star and one on your telephone keypad. A confirmation tone will indicate that your line is in the question queue. You may press star two if you would like to leave the question queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. The first question comes from Mike Matson of Needham & Company. Thanks for taking my questions. Let's see. I guess I'll start with the comment around things you've done to reduce the cash burn. Can you maybe just talk a little bit more about the sequential approach and, you know, how that might affect the timing of any of the test launches? Yeah, Mike, we will, and I appreciate the question. You know, our goal right now is all about focus, focus. Right now we have two, we believe, immediate revenue opportunities to complement DetermaRx. Obviously we're gonna continue all the efforts around DetermaRx, but we are gonna throttle back on some of the clinical studies that were planned for DetermaRx, and so to expand utility, et cetera. Those will be reprioritized, and we'll put energy behind DetermaIO to get it submitted for CMS. Keep in mind, we've got enough data, we believe after ASCO and the upcoming publications of the data that's already been presented to submit for at least two indications. That's what we're gonna go to market with. We have planned, I think as you know, to try to get a few more studies under our belt and to try to present the case for a pan-cancer reimbursement. Right now we decided that to minimize the cost, and obviously there's risk anytime you go do clinical studies. We're gonna take what we got, and we're gonna go forward with that. It won't delay the launch of DetermaIO, but it will mean that we focus DetermaIO's launch into triple-negative breast cancer, non-small cell lung cancer and potentially bladder cancer now that we have the AACR paper behind us. Transplant, of course, we were way down the road on transplant. We beat our timelines that we set for the team to end by the end of June. They finished the LCD. I'm sorry, they finished the LDT at the end of March, and they finished the LCD a couple weeks ago, and we announced that last week. We believe that we're poised for launch for our transplant business in the fall. We'll be shifting some of the planned sales force expansion oncology over to transplant, so that we can have someone representing our transplant offering for liver in the marketplace by fall. The real only delay that we anticipate might be pushing out DetermaCNI and potentially DetermaTx launches, just based on how we have to sequentially plan these things without adding new marketing headcount. That's really the big challenge now is just to make sure we stay focused on transplant and getting IO submitted. After that, we'll begin the sequential follow-on of the other products. We're not expecting quote-unquote years delay. We're expecting quarter delays in some of the other products that were mentioned today. Okay. Got it. That's helpful. Just any updates on the potential platform deal for TheraSure? It sounds like Mitch mentioned that, you know, they're still being discussed, but I guess I thought we might hear something, you know, kinda by the spring or early summer timeframe. Is that still the case? Yeah. Mike, we are at the 11th hour with the digital PCR opportunity, and we're down the road on a next gen sequencing opportunity as well. It's very plausible that we might end up on two platform technologies, next sequencing and digital PCR. We'll definitely be announcing very soon the primary relationship that we're looking to execute on in digital PCR. Just stay tuned for that. I just can't announce it yet 'cause we aren't finalized the contract with signatures on both sides yet. Okay. Got it. Thank you. The next question comes from Mark Massaro of BTIG. Hey, guys. Thank you for taking the questions. Ronnie, I think you mentioned that you may move a small number of your reps over from oncology to transplant. I mean, is that literally one or two folks? Then can you give us a sense for now that the liver transplant test is validated, you know, I think you indicated in the press release a launch seems to be imminent, but maybe can you just talk about, you know, when exactly that will launch and then talk about some of the logistics out of your lab on the east coast? Yeah, absolutely. First off, Mark, just to be clear, we're not gonna take anyone from oncology sales and move them to transplant. If you remember, we're planning on doubling, pretty much doubling the oncology sales force this year. We're gonna put those plans on the back burner for now, and we're gonna take some of those headcount we have planned and move over, and we'll hire a team to sell transplant that comes from the transplant industry or transplant marketplace. So that's the first thing. The second thing is we did absolutely complete the LDT validation for liver. The LCD was also completed and submitted, so we are in a waiting phase to hear from CMS. Our goal is also to try to submit, as we committed, kidney as well by the end of June. All those are in process. Our goal is gonna be to begin to establish. We've already established the lab processes. We have a really good workflow. We have a team in Nashville prepared to take samples. Now it's really about executing, to your point, the logistics of how we're going to get the sample collected, how we're gonna get those samples into our lab. All that's being worked on now, and we expect to have all that in place by the time we get reimbursement. You know, who knows at this point, given where CMS is from a timeline perspective, but we expect early fall we'd be ready to go for a market launch with reimbursement. That's what we believe based on what we know about CMS's backlog today. Okay. That's helpful. Thanks for clarifying that. Obviously DetermaRx will remain a commercial focus for OncoCyte. Did I hear you say that you may throttle back on clinical study development on Rx? If that's the case, should we be maybe pushing out our own expectations for when Rx could be included into NCCN guidelines? Yeah. I think that's the big question mark. You hit the nail on the head. We have a randomized clinical trial open. It is enrolling at a slow pace. Patients have not necessarily wanted to randomize themselves, knowing how powerful our data is at selecting patients that have high risk, and the outcome that they take chemo obviously is profound. Our goal is not to add any additional studies around that. We have an open registry. We'll keep the registry open, and we'll keep the current slow intake of RCT, but we're not gonna add any of the other trials that we were considering that might have accelerated a data set for NCCN by next summer. Those would be risky to get them done in that timeframe. We just said given the risk and given the burn it would take to get there, and we just decided it's probably better to let the current trials continue to go forward and not add any additional expense to that. Okay. Maybe one last question, and I'll hop back in the queue. The $40,000 of licensing revenue, I believe, came from Burning Rock, for the launch of Rx in China. Yep. Pretty sure Shanghai is on lockdown. I guess, can you just talk about, I assume that, you know, things are definitely on alert in China, especially in Shanghai. Can you give us a sense for, you know, Burning Rock's focus on that test and, maybe just describe the impact that you saw as a result of the lockdown in Shanghai? Yeah, I'm going to let Mitch answer that. I think everyone knows Mitch was on point for the whole since the beginning and really did all the negotiations with our Chinese partner. Again, kudos to Mitch for the hard work there. Mitch stays on the phone with them. What's the latest? We do know we're being impacted by the lockdown for sure. Yeah, definitely impacted by the lockdown. They are committed to Rx. They've done studies around it. They've commercialized it now for about five consecutive months and are showing good progress. You're right, you know, Mark. China is exceptional in their lockdown regarding COVID, and that's gonna have an impact. Okay, thanks for the time. I'll hop back in the queue. Thanks, Mark. Thank you. The next question comes from David Westenberg of Piper Sandler. Hi. Thank you for taking the questions. I just have two, I think short ones. First off, just a clarity on all the cash metrics here. I think you exited 2024, you did a $32 million deal. That puts your current cash balance somewhere around $50. Does that make sense? You gave this cash runway to 2024. I just wanna make sure clear that it's through. Was it to 2024 or through 2024? You said it does add in some of the non-dilutive capital assumptions. Can you clarify whether some of that non-dilutive capital assumptions are stuff that hasn't been announced yet, or is it everything you kind of already talked about so far? Sure, yeah. Mitch is gonna take that one. Mitch. David, you're fairly accurate on the cash number. I'd say in the low fifties is probably a little more accurate. We do anticipate it bringing in another $10 million in our preferred offering with two of our institutional investors. That'll come in two tranches of $5 million each. One will close in the second quarter, one will close in the fourth quarter. Additionally, we can't delve into details regarding non-dilutive financing and capital sources, specifically 'cause that's. We're a public company, we just can't tell you, David. Yeah. We're not allowed to. I just wanted to make sure. It does contemplate stuff that has not yet. That's correct. It does contemplate things that have not been disclosed, and we expect that capital, combined with what we currently have on the books and bringing in the $10 million from our preferred, will get us into 2024. How far into 2024 is gonna be dependent upon how we're able to scale back our plans. David, let me just say this. I think that we are. It's not like we're hoping for those non-dilutive things. We're actually in discussions around some things, so we just can't comment on them 'cause they're not completed yet. Perfect. No, that's helpful. Then just quickly on account access. You know, you onboarded, I think you have 472 onboarded accounts, you know, up 10%, but, you know, the test orders was up 73%. Can you maybe talk about, it sounds like there's order frequency trends going on, and just wanna maybe clarify that and- Yeah. We are seeing. Well, one of the things we did, David, given the lockdown, coming out of the lockdown, if you remember, we had onboarded a lot of people virtually, but a rep had not been in to basically detail the surgeon itself or himself or herself. With things opening up, our sales team was able to start getting in and doing that. As a result of that, you're seeing an increase in sample volume from same-store sales, if you will, or same sites that we've already gotten some. Now we get more physicians onboarded there, and they begin to order. You know, we expect that that is a better use of our sales team's time. We spend all this energy at getting these new accounts. While we do wanna continue to grow our account base, our original wave of account access and effort was focused on high incidence rate areas. As you know, DetermaRx is a smaller market opportunity. With IO and TX coming, we wanted our reps to have a presence and a brand presence in these high incidence rate accounts, and that's what we focused on. Now that things are opening up, we wanna start really penetrating the current accounts and driving more utility of our products. We think it's a better, more efficient use of their sales time. All right. Thank you so much. Thanks, David. Thanks, Dave. Thank you. The next question comes from Paul Knight of KeyBanc. Hey, Ryan. On the TheraSure, what should we think about regarding pricing for that particular type of test? Yeah. Today, kidney is our digital PCR methodology was given a blanket LCD a year ago, and it was given for kidney at $2,700 and heart for $2,850, I believe. We think liver will be somewhere in that range, but hard to tell. But it's the same technology, same methodology, a little more important outcome given given the number of biopsies, et cetera. We think that there's probably a good degree of probability that we'll fall between the $2,700 and $2,800 dollar range. Isn't this a multiple test per year per patient type test? Correct. Yeah. That depends on, you know, European standard of care is a little different than the U.S., but we're looking and we think somewhere between, you know, seven at least, you know, seven in year one and four, which is very similar to kidney and heart. Somewhere in that follow-up, you know, utility for follow-up, you'll see liver follow more than likely. Okay. Regarding Rx in the quarter, the pricing seems to be up. Is that a fair assumption? Yeah, that's a great point, Paul. We, we've been attacking the private payers pretty hard and hand-to-hand combat adjudication the claims. Mitch, I mean, you're nodding. I mean, I thought we saw a really nice quarter of being able to collect cash. Yes. Actually move some of the folks that have underpaid us up to a better standard for us. The answer, yeah, is yes, Paul. As you know, though, we always say this, that we are not in contract with, except for one, a small payer, and every private claim has to be adjudicated typically. We have a team that's doing that, so they're obviously gaining some steam. We do believe the addition of DetermaIO and DetermaTx will add more value to our market access team because now they've got more in a position for contracting. Hopefully we'll see some gains out of that group in terms of actually getting on contract, but probably not until we're ready to launch TX and IO. Okay. Lastly, regarding the services group business, is that kinda steady state for the foreseeable future? Yeah, you know, Paul, it's weird. I've been watching other, you know, folks, you know, report, and we've heard several times from different companies that their pharma businesses are down and that they felt like the surge, you know, the winter surge that people stayed away from some of the clinical studies. I have to be honest, it doesn't make sense to me if you're a cancer patient, why you'd not go and get into the trial. The reality is, we did see and hear from other companies. We do have a really robust contracted pipeline, but until we see patient samples, we can't bill against those. We'll see. I think it's gonna be lumpy this year. We had hoped it would be a little more predictable, but it looks like it might be as lumpy this year as last year, given the you know, the challenges that our pharma partners are having recruiting patients. Okay. Thank you. Thank you. The next question comes from Thomas Flaten of Lake Street Capital Markets. Hey, guys. Appreciate you taking the questions. Yeah, Tom. Just, with respect to the launch of DetermaIO, you mentioned that you might be shifting some of the planned headcount from the oncology team over to the up-and-coming transplant team. Can you just talk a little bit about how we should think about the DetermaIO and DetermaRx growth curves given what seems to be a smaller commercial infrastructure that you're planning? Yeah, absolutely. I kinda started there on an earlier question, but let me be a little more specific. When we launched and deployed our original 10 reps, we thought, and we think we did a good job of choosing high incidence rate or high incidence areas for our sales reps to be deployed. Throughout the pandemic, that proved to be true because we were able to onboard docs, but without having more than the 10 reps. We added three, you know, in Q1, we have 13 now. Our goal by the end of the year was to have that into the low 20s probably and expand into some new territories. Instead what we're gonna do is take the current territories, and we're gonna focus on, as we launch IO and TX and they get reimbursement, we're gonna focus more on the current territories and going deeper into the accounts and gaining a better, faster traction for IO and TX. As you guys know, TX is a blanket LCD, so we still expect it to get reimbursed fairly rapidly once we submit it. The idea would be instead of expanding outward, actually going deeper into accounts. Some of our accounts, like Florida Cancer Specialists or Georgia Cancer Specialists, you know, there's multiple physicians, Texas Oncology, multiple physicians within those accounts. The idea is instead of onboarding an account and getting one or two docs, we wanna onboard the account and go deep within the account. You know, the sort of infrastructure of those accounts and drive utility across positions within the account versus add new territory. You know, look, as we get through the current market storm and as we launch these products and revenues begin to grow, we'll take a deep breath and see if it's, you know, when the right time is to add new territories. Today, that's the specifics around what we're planning to do around the oncology business. If I might, you made reference to CMS a couple of times with respect to timing. In response to an earlier question, did I hear, maybe I might have misheard, but did you say you're gonna submit here shortly the LCD, but you expected to have a response in the early fall? Did I hear that right? That seemed a bit aggressive from a timing perspective. Thomas Flaten, if you keep in mind, the transplant LCD is a blanket LCD for digital PCR, and we submitted liver two weeks ago, but liver does not have a, is not part of the blanket LCD. There's nobody with a liver test today, as you know, so we're the first ones out. Kidney and heart are reimbursed already using digital PCR. You know, we don't know for sure, but we believe that given there's kidney and heart, we should receive a rapid review of the LCD, given there's already a blanket LCD written for our technology that cited our papers. The timing on IO, do you think would be similar to this? DetermaIO, we're still on track. Yeah, we're waiting on one publication to be accepted and us notified. Once that happens, we're gonna prepare. You know, we've been working on the dossier, so our goal is to submit DetermaIO, as we've said, somewhere by the end of summer. Got it. Appreciate it. Thanks so much. Thank you, Thomas. The next question comes from Mason Carrico of Stephens Inc. Hey, guys. Most of my questions. Hey, Mason Have been answered here. Maybe just one quick one. On TheraSure, any color you could provide around recent discussions with transplant centers, how should we kind of think about the opportunity between centers versus more community-based centers? Is one a more, you know, a more near-term target? I'd assume it'd be the transplant centers versus the community centers themselves. Just any color there you could provide. Yeah. I mean, you know, I think the thing that's in our favor is today there's no molecular test for liver in the market validated today. We are kind of the first out in that indication. The good news is there's some great competitors already out there, CareDx, Natera, and the other indications, and they've done a terrific job of the missionary marketing work to sort of convince transplant physicians the need for molecular testing. We certainly believe that has created an awareness of what we're doing. Our initial engagement with the various centers we talked to has been very positive, and they have acknowledged the need for what we're bringing, and they certainly are excited about a rapid turnaround time that we can provide out of our lab. you know, those things, you know, the jury's out on that till we start hitting the. The rubber meets the road when our reps start going in and trying to start getting samples in. But we certainly have received a very positive feedback from the key opinion leaders that we talked to in liver in these large centers. Got it. Thanks, Ed. Thanks, Mason. Thanks, Mason. The final question comes from Bruce Jackson of The Benchmark Company. Hi, thanks for taking my questions. With regard to the TheraSure launch, where are you in terms of your launch preparations in terms of the sales force, clinical support, things like that? Yeah. We are, you know, the lab came first, we've got the lab in place, the workflow is in place, the LDT is final. We have, we're working obviously on the logistical components of that now, which will include the requisition to order as well as the how we're gonna return results via a report electronically versus PDF. Even crazy as it sounds, a lot of these facilities still prefer a PDF and a fax. We sometimes scratch our head at that, but that's still the case in many instances. But we are working on an electronic, you know, report as well. All those things are in process. Again, we wanted to wait and make the investment behind those till we saw a successful workflow in LDT. Those are now complete. By the time we get reimbursement, we expect we'll be a fully functional battle star in transplant. Okay. Just real quick on the DetermaTx and DetermaCNI timelines, how far should we be thinking about shifting those out? I think the DetermaCNI timeline is the one that's at the greatest risk, candidly, because right now we are not gonna unless we find an appropriate partner that wants to do some studies with us and keep them fairly cost neutral for us, we'll probably not invest behind those studies. We'll launch it as an RUO in the United States for pharma and hope we can solicit some of that support from pharma. Right now, that's the one that's at the most risk. We had originally planned to launch it, which we will as an RUO this summer, but we had hoped to maybe actually submit for reimbursement later in the year. I think, given where we are financially and the need to conserve cash, that we'll have to wait till we find a stronger partner relationship where they'll help fund some of that effort. I am unsure about how long that'll push it out, but I wouldn't expect a long time 'cause we do have some good conversations underway. I would not expect any revenue from CNI in the next 12 months outside of an RUO project with pharma. Okay. That's it for me. Thank you very much. Thanks, Bruce. Thanks, Bruce. That was the final question. Ladies and gentlemen, we have reached the end of the question- and- answer session. This concludes today's conference call. Thank you for your participation. You may now disconnect your lines.